Eko, a Silicon Valley digital health company applying machine learning in the fight against heart disease, announced Eko Home touting it as a first-of-its-kind service that enables precise remote monitoring of cardiac function using ECG and heart sounds. Eko Home can be used to create drug-data combinations to demonstrate real-world efficacy for pharma trials, while simultaneously allowing clinicians to collect high-quality data while outside of the clinical environment.

The Eko Home application is currently being used in an active Mayo Clinic study. The purpose of the study is to evaluate different strategies of cardiovascular therapy with carvedilol aiming to reduce the incidence of heart function declines and heart failure in at-risk breast cancer patients while on trastuzumab therapy.

“Eko Home provides a critical monitoring and data collection component for clinical studies leveraging the power of machine learning to improve all types of clinical analysis,” Connor Landgraf, CEO of Eko, said in a statement. “This valuable insight offers researchers and healthcare professionals reliable cardiac data to make better judgements, recommendations, or adjustments to their research.”

Eko expects to offer the drug-data combinations with other life science partners by the end of the year with additional plans to offer its SDK to hospitals and healthcare providers that wish to build the platform directly into their applications.